Franklin Resources
ATRA icon

Franklin Resources’s Atara Biotherapeutics ATRA Stock Holding History

Franklin Resources’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-921
Closed -$11.8K – 2874
2023
Q4 		$11.8K Hold
921
– – ﹤0.01% 2595
2023
Q3 		$34.1K Sell
921
-243
-21% -$10.8K ﹤0.01% 2562
2023
Q2 		$46.9K Sell
1,164
-11
-0.9% -$622 ﹤0.01% 2617
2023
Q1 		$85.2K Buy
1,175
+313
+36% +$30.4K ﹤0.01% 2132
2022
Q4 		$70.6K Sell
862
-136
-14% -$14.2K ﹤0.01% 2170
2022
Q3 		$94K Buy
998
+179
+22% +$20.1K ﹤0.01% 2112
2022
Q2 		$159K Sell
819
-398
-33% -$65K ﹤0.01% 2068
2022
Q1 		$283K Sell
1,217
-3
-0.2% -$955 ﹤0.01% 2038
2021
Q4 		$480K Hold
1,220
– – ﹤0.01% 1919
2021
Q3 		$546K Buy
+1,220
New +$437K ﹤0.01% 1850

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Franklin Resources's ATRA Position: Q1 2024 in Review

Franklin Resources sold out of Atara Biotherapeutics (ATRA) in Q1 2024, closing a stake of 921 shares — an estimated $11.8K sold.

Franklin Resources first reported a position in ATRA in Q3 2021 and held it in 10 quarters. The position peaked at $546K in Q3 2021. 82 funds tracked by Wall St. Rank hold ATRA as of Q1 2024.

  • Franklin Resources reported no remaining Atara Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Franklin Resources sold 921 Atara Biotherapeutics shares in Q1 2024, an estimated $11.8K.
  • Franklin Resources first reported a position in Atara Biotherapeutics in Q3 2021 and held it in 10 quarters.
  • Franklin Resources's Atara Biotherapeutics position peaked at $546K in Q3 2021.
  • 82 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2024.

Based on Franklin Resources's 13F filing for Q1 2024, filed 13 May 2024.